Food | Page 163 of 210 | SpiritIndia.com

Health :: Glivec, imatinib approved for five rare life threatening disorders

In another important milestone, Glivec? (imatinib) has received US regulatory approval to help patients with five distinct and potentially life-threatening disorders, representing the first time that a regulatory authority has ever simultaneously approved one targeted medicine for so many disorders. With today’s decision, and in only five years, Glivec has now been approved in the US for seven diseases, including two solid tumors and five blood disorders with molecular targets known to be inhibited by the drug.

Bipolar Depression :: AstraZeneca’s SEROQUEL for Bipolar Depression Treatment

AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved SEROQUEL? (quetiapine fumarate) for the treatment of patients with depressive episodes associated with bipolar disorder. SEROQUEL already is approved for the treatment of acute manic episodes associated with bipolar I disorder and for the treatment of schizophrenia. SEROQUEL is now the first and only single medication approved by the FDA to treat both depressive and manic episodes associated with bipolar disorder.

HIV :: REYATAZ, atazanavir sulfate for Adults With HIV-1 Infection

Bristol-Myers Squibb Company (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has granted approval of a new 300 mg single capsule formulation of REYATAZ? (atazanavir sulfate) for the treatment of HIV-1 infection in adults as part of combination therapy. Taken once daily along with ritonavir and food as part of a anti-HIV drug regimen, the REYATAZ 300 mg single capsule formulation can replace two REYATAZ 150 mg capsules for: patients who have previously received anti-HIV medicines, patients who will be receiving tenofovir disoproxil fumarate, and patients who have never taken anti-HIV medicines that require SUSTIVA? (efavirenz) as part of their anti-HIV drug regimen. The REYATAZ single capsule formulation will be available in the United States within seven business days.

Hunter Syndrome :: ELAPRASE, idursulfase – therapy for Hunter syndrome patients in Europe

Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) today reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) issued a positive opinion recommending approval of ELAPRASE for the long-term treatment of patients with Hunter syndrome (Mucopolysaccharidosis II). The EU Marketing Authorisation is expected early in 2007 and will result in unified labelling that will be valid in the current EU 25 member states as well as in Iceland and Norway.

Diabetes :: FTC and FDA Act Against Internet Vendors of Fraudulent Diabetes Cures

The Federal Trade Commission (FTC) and the Food and Drug Administration (FDA), working with government agencies in Mexico and Canada, have launched a drive to stop deceptive Internet advertisements and sales of products misrepresented as cures or treatments for diabetes. The ongoing joint campaign has so far included approximately 180 warning letters and other advisories sent to online outlets in the three countries.

Renal Cell Carcinoma :: High bread consumption linked with renal cell carcinoma

A case-control study of more than 2300 Italians has found a significant association between high bread consumption and renal cell carcinoma. Eating a lot of pasta and rice may also raise the risk, while eating many vegetables may lower the risk. The study published online October 20, 2006 in the International Journal of Cancer, the official journal of the International Union Against Cancer (UICC).

Cancer :: Taxotere, docetaxel by Sanofi-Aventis for Advanced Head and Neck Cancer

The Food and Drug Administration (FDA) approved Taxotere (docetaxel) Injection Concentrate for use in combination with cisplatin and fluorouracil prior to radiotherapy for the treatment of patients with inoperable, locally advanced squamous cell carcinoma of the head and neck (SCCHN). This disease represents approximately 3 percent of all new cancer cases in the United States.

Diet :: Hospital food could lack nutritional value

Substantial nutrient loss in food occurs in hospital foodservice operations, according to research recently published in the Journal of Foodservice. The study quantifies how much Vitamin C, as a marker of nutrient quality, is retained at various stages of processing at two New Jersey hospitals.

Diabetes :: JANUVIA, sitagliptin phosphate – the First and Only DPP-4 Inhibitor for Type 2 Diabetes

Merck & Co., Inc. announced today that the U.S. Food and Drug Administration (FDA) approved JANUVIA (sitagliptin phosphate), the first and only DPP-4 inhibitor available in the United States for the treatment of type 2 diabetes. JANUVIA has been approved as monotherapy and as add-on therapy to either of two other types of oral diabetes medications, metformin or thiazolidinediones (TZDs), to improve blood sugar (glucose) control in patients with type 2 diabetes when diet and exercise is not enough. The recommended dose of JANUVIA is 100 mg once daily. JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.

Diabetes :: Top 5 Diabetes Diet Tips for Creating Healthy Meal Plan

Diet plays a key role in controlling your blood sugar. A healthy-eating plan tailored to your needs will do that and more. Majority of people affected with diabetes are overweight or obese. In fact, your risk of getting diabetes increases the more weight you put on.